FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895586755> ?p ?o ?g. }

• W2895586755 endingPage "425" @default.
• W2895586755 startingPage "418" @default.
• W2895586755 abstract "The number of prostate biopsy cores that need to be taken from each magnetic resonance imaging (MRI) region of interest (ROI) to optimize sampling while minimizing overdetection has not yet been clearly elucidated. To characterize the incremental value of additional MRI-ultrasound (US) fusion targeted biopsy cores in defining the optimal number when planning biopsy and to predict men who might benefit from more than two targeted cores. This was a retrospective cohort study of MRI-US fusion targeted biopsies between 2015 and 2017. MRI-US fusion targeted biopsy in which four biopsy cores were directed to each MRI-targeted ROI. The MRI-targeted cores representing the first highest Gleason core (FHGC) and first clinically significant cancer core (FCSC; GS ≥ 3 + 4) were evaluated. We analyzed the frequency of FHGC and FCSC among cores 1–4 and created a logistic regression model to predict FHGC >2. The number of unnecessary cores avoided and the number of malignancies missed for each Gleason grade were calculated via clinical utility analysis. The level of agreement between biopsy and prostatectomy Gleason scores was evaluated using Cohen's κ. A total of 479 patients underwent fusion targeted biopsy with four individual cores, with 615 ROIs biopsied. Among those, FHGC was core 1 in 477 (76.8%), core 2 in 69 (11.6%), core 3 in 48 (7.6%), and core 4 in 24 men (4.0%) with any cancer. Among men with clinically significant cancer, FCSC was core 1 in 191 (77.8%), core 2 in 26 (11.1%), core 3 in 17 (6.2%), and core 4 in 11 samples (4.9%). In comparison to men with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 5, patients were significantly less likely to have FHGS >2 if they had PI-RADS 4 (odds ratio [OR] 0.287; p = 0.006), PI-RADS 3 (OR 0.284; p = 0.006), or PI-RADS 2 (OR 0.343; p = 0.015). Study limitations include a single-institution experience and the retrospective nature. Cores 1–2 represented FHGC 88.4% and FCSC 88.9% of the time. A PI-RADS score of 5 independently predicted FHGC >2. Although the majority of cancers in our study were appropriately characterized in the first two biopsy cores, there remains a proportion of men who would benefit from additional cores. In men who undergo magnetic resonance imaging-ultrasound fusion targeted biopsy, the first two biopsy cores diagnose the majority of clinically significant cancers. However, there remains a proportion of men who would benefit from additional cores." @default.
• W2895586755 created "2018-10-12" @default.
• W2895586755 creator A5015235928 @default.
• W2895586755 creator A5019845487 @default.
• W2895586755 creator A5030609254 @default.
• W2895586755 creator A5031300891 @default.
• W2895586755 creator A5043129088 @default.
• W2895586755 creator A5062397416 @default.
• W2895586755 creator A5071054112 @default.
• W2895586755 date "2018-10-01" @default.
• W2895586755 modified "2023-10-16" @default.
• W2895586755 title "Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy" @default.
• W2895586755 cites W1254243997 @default.
• W2895586755 cites W1590853871 @default.
• W2895586755 cites W1663630120 @default.
• W2895586755 cites W1736500210 @default.
• W2895586755 cites W1995589176 @default.
• W2895586755 cites W2028481796 @default.
• W2895586755 cites W2037789405 @default.
• W2895586755 cites W2048714893 @default.
• W2895586755 cites W2095284457 @default.
• W2895586755 cites W2117211285 @default.
• W2895586755 cites W2146373036 @default.
• W2895586755 cites W2148214708 @default.
• W2895586755 cites W2157814660 @default.
• W2895586755 cites W2291326553 @default.
• W2895586755 cites W2292160450 @default.
• W2895586755 cites W2415643292 @default.
• W2895586755 cites W2514563112 @default.
• W2895586755 cites W2538662995 @default.
• W2895586755 cites W2571897894 @default.
• W2895586755 cites W2598006157 @default.
• W2895586755 cites W2604294081 @default.
• W2895586755 cites W2754940790 @default.
• W2895586755 cites W2767138393 @default.
• W2895586755 cites W2768484936 @default.
• W2895586755 cites W2786814545 @default.
• W2895586755 cites W2789982652 @default.
• W2895586755 cites W2790500443 @default.
• W2895586755 cites W2793905111 @default.
• W2895586755 cites W2805225705 @default.
• W2895586755 cites W778629108 @default.
• W2895586755 cites W853957662 @default.
• W2895586755 doi "https://doi.org/10.1016/j.euo.2018.09.006" @default.
• W2895586755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31158081" @default.
• W2895586755 hasPublicationYear "2018" @default.
• W2895586755 type Work @default.
• W2895586755 sameAs 2895586755 @default.
• W2895586755 citedByCount "46" @default.
• W2895586755 countsByYear W28955867552019 @default.
• W2895586755 countsByYear W28955867552020 @default.
• W2895586755 countsByYear W28955867552021 @default.
• W2895586755 countsByYear W28955867552022 @default.
• W2895586755 countsByYear W28955867552023 @default.
• W2895586755 crossrefType "journal-article" @default.
• W2895586755 hasAuthorship W2895586755A5015235928 @default.
• W2895586755 hasAuthorship W2895586755A5019845487 @default.
• W2895586755 hasAuthorship W2895586755A5030609254 @default.
• W2895586755 hasAuthorship W2895586755A5031300891 @default.
• W2895586755 hasAuthorship W2895586755A5043129088 @default.
• W2895586755 hasAuthorship W2895586755A5062397416 @default.
• W2895586755 hasAuthorship W2895586755A5071054112 @default.
• W2895586755 hasConcept C106131492 @default.
• W2895586755 hasConcept C121608353 @default.
• W2895586755 hasConcept C126322002 @default.
• W2895586755 hasConcept C126838900 @default.
• W2895586755 hasConcept C140779682 @default.
• W2895586755 hasConcept C143409427 @default.
• W2895586755 hasConcept C159985019 @default.
• W2895586755 hasConcept C192562407 @default.
• W2895586755 hasConcept C2164484 @default.
• W2895586755 hasConcept C2775934546 @default.
• W2895586755 hasConcept C2776235491 @default.
• W2895586755 hasConcept C2779466945 @default.
• W2895586755 hasConcept C2780192828 @default.
• W2895586755 hasConcept C2781217009 @default.
• W2895586755 hasConcept C2989005 @default.
• W2895586755 hasConcept C31972630 @default.
• W2895586755 hasConcept C41008148 @default.
• W2895586755 hasConcept C71924100 @default.
• W2895586755 hasConceptScore W2895586755C106131492 @default.
• W2895586755 hasConceptScore W2895586755C121608353 @default.
• W2895586755 hasConceptScore W2895586755C126322002 @default.
• W2895586755 hasConceptScore W2895586755C126838900 @default.
• W2895586755 hasConceptScore W2895586755C140779682 @default.
• W2895586755 hasConceptScore W2895586755C143409427 @default.
• W2895586755 hasConceptScore W2895586755C159985019 @default.
• W2895586755 hasConceptScore W2895586755C192562407 @default.
• W2895586755 hasConceptScore W2895586755C2164484 @default.
• W2895586755 hasConceptScore W2895586755C2775934546 @default.
• W2895586755 hasConceptScore W2895586755C2776235491 @default.
• W2895586755 hasConceptScore W2895586755C2779466945 @default.
• W2895586755 hasConceptScore W2895586755C2780192828 @default.
• W2895586755 hasConceptScore W2895586755C2781217009 @default.
• W2895586755 hasConceptScore W2895586755C2989005 @default.
• W2895586755 hasConceptScore W2895586755C31972630 @default.
• W2895586755 hasConceptScore W2895586755C41008148 @default.
• W2895586755 hasConceptScore W2895586755C71924100 @default.

• next